Top Stories
The startup already has a $30-million-plus co-development and licensing deal with a Fortune 100 healthcare company and is working with NVIDIA to scale its medical AI models.
NeoImmune is eligible for up to $260 million in development and sales milestones.
The mAb reduced new heterotopic ossification lesions by 90% or more in a Phase III trial of patients with fibrodysplasia ossificans progressiva (FOP).
Heidi Overton's nomination must be confirmed by the Senate before she takes the reins as the next FDA commissioner.
The alliance, forged in 2023, centred on using TScan's target discovery platform to identify antigens recognised by T-cells in patients with Crohn's disease.
Conference News
NANJING, China, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinica...
Adding a personalised cancer vaccine to standard-of-care immunotherapy slowed recurrence of melanoma and reduced the risk of it spreading to other parts of the body, new Phase III data has confirmed. Patients enrolled in the study had previously undergone surgery.
Real-world evidence on NSCLC treatment patterns and outcomes showcases Flatiron's unified, global oncology engineNEW YORK--(BUSINESS WIRE)-- Flatiron Health today announced its presence at the IASLC 2...
Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mu...
CAMBRIDGE, Mass., Aug. 19, 2026 /PRNewswire/ -- Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines fo...
